Want to understand why cancer cells metastasize? Think of Sparta.Ancient Greek warriors were fed a special diet that better prepared them for the demands of battle on distant fields.
Strong association discovered between telomere length and increased risk of melanoma
9/23/2014
A leading Dartmouth researcher, working with The Melanoma Genetics Consortium, GenoMEL, an international research consortium, co-authored a paper published in the Journal of the National Cancer...
MRIs enable non-invasive tracking of emerging cell therapies
9/23/2014
Cellular therapeutics - using intact cells to treat and cure disease - is a hugely promising new approach in medicine but it is hindered by the inability of doctors and scientists to effectively...
New cancer drug target involving lipid chemical messengers
9/23/2014
More than half of human cancers have abnormally upregulated chemical signals related to lipid metabolism, yet how these signals are controlled during tumor formation is not fully understood.
Palliative care not available for many patients with terminal cancer
9/23/2014
Many patients with advanced, incurable cancer do not receive any palliative care, reveals new research to be presented later this month at the ESMO 2014 Congress in Madrid, Spain, 26-30 September.
Freeing the immune system to destroy cancer
9/23/2014
Research led by Paulo Rodriguez, PhD, an assistant research professor of Microbiology, Immunology & Parasitology at LSU Health New Orleans' Stanley S.
Inpatient statin use linked to better health outcomes after brain hemorrhage
9/23/2014
Researchers have found that the use of statins after a hospitalization for intracerebral hemorrhage is associated with improved health outcomes for patients.
E-cigarettes 'not helping cancer patients to quit smoking'
9/22/2014
Despite an increasing number of cancer patients turning to e-cigarettes to aid smoking cessation, a new study suggests that they could be having little effect.
Gilead Sciences, Inc. has announced that the European Commission has granted marketing authorisation for Zydelig (idelalisib), 150 mg tablet, a first-in-class oral treatment for two incurable blood...
Gilead Sciences, Inc. has announced that the European Commission has granted marketing authorisation for Zydelig (idelalisib), 150 mg tablet, a first-in-class oral treatment for two incurable blood...